iMeds.se

Alendronat Hexal

Document: Alendronat HEXAL 10 mg tablet ENG SmPC change

Summary of product characteristics


1. NAME OF THE MEDICINAL PRODUCT

Alendronat HEXAL 10 mg tablets


2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each tablet contains 10mg alendronic acid (as sodium alendronate trihydrate).


Excipient with known effect:

Each tablet contains 98.8 mg lactose.


For the full list of excipients see section 6.1.


3. PHARMACEUTICAL form

Tablet


White to off-white, capsule-shaped tablet, embossed with "AN 10" on one side and "Arrow logo" on the other.


4. Clinical particulars


4.1 Therapeutic indications


- Treatment of post-menopausal osteoporosis. Alendronate reduces the risk of vertebral and hip fractures.

- Treatment of osteoporosis in men at increased risk of fracture. A reduction in the incidence of vertebral, but not of non-vertebral fractures has been demonstrated.

- Treatment and prophylaxis of glucocorticoid-induced osteoporosis (see section 5.1).


4.2 Posology and method of administration


The optimal duration of bisphosphonate treatment for osteoporosis has not been established. The need for continued treatment should be re-evaluated periodically based on the benefits and potential risks of alendronate on an individual patient basis, particularly after 5 or more years of use.


Posology


Post-menopausal osteoporosis

The recommended dosage is 10 mg once daily.


Osteoporosis in men

The recommended dosage is 10 mg once daily.


Glucocorticoid-induced osteoporosis

For post-menopausal women who are not receiving oestrogen treatment the recommended dose is one 10 mg tablet daily. For other populations, see summary of product characteristics for preparations that contain 5 mg alendronate.


Elderly

In clinical trials there was no age-related difference with regard to efficacy or safety profiles of alendronate. Therefore no adjustment of the dose is necessary for elderly patients.


Renal impairment

No dose adjustment is necessary in patients with a glomerular filtration rate (GFR) greater than 35 ml/min. Alendronate is not recommended for patients with impaired renal function if the GFR is less than 35 ml/min, as there is no experience of this.


Hepatic impairment

No dose adjustment is necessary.


Paediatric patients

Alendronate sodium is not recommended for use in children under the age of 18 years due to insufficient data on safety and efficacy in conditions associated with paediatric osteoporosis (also see section 5.1).


Method of administration


For oral use only.


To obtain satisfactory absorption of alendronate

Alendronat Hexal tablets must be taken on an empty stomach immediately on rising in the morning, with plain water only, at least 30 minutes before the first food, drink or other medication of the day. Other drinks (including mineral water), food and some medicines are likely to reduce the absorption of alendronate (see section 4.5).


To assist delivery to the stomach and thus reduce the risk of irritation/side effects locally and in the oesophagus (see section 4.4)


Patients should be given a calcium and vitamin D supplement if the diet is inadequate (see section 4.4).


4.3 Contraindications



4.4 Special warnings and precautions for use


Upper gastrointestinal adverse reactions

Alendronate can cause local irritation to the upper gastrointestinal mucosa. As there is a risk of worsening of the underlying disease, caution should be observed if alendronate is given to patients with active upper gastrointestinal tract problems, such as dysphagia, oesophageal disease, gastritis, duodenitis or ulcers, or in cases of recent (during the last year) severe gastrointestinal disease such as gastric ulcer, active gastrointestinal bleeding or surgery in the upper gastrointestinal tract other than pyloroplasty (see section 4.3). In patients with known Barrett's oesophagus, prescribers should consider the benefits and potential risks of alendronate on an individual patient basis.


Oesophageal side effects (in some cases severe and requiring hospitalisation) such as oesophagitis, oesophageal ulcers or oesophageal erosions, in rare cases followed by oesophageal stricture or perforation, have been reported in patients receiving treatment with alendronate. The physician should therefore be alert to any signs or symptoms of possible oesophageal reaction. The patients should be instructed to discontinue alendronate and seek medical attention if they develop symptoms of oesophageal irritation such as dysphagia, pain on swallowing, retrosternal pain or new/worsened heartburn.


The risk of severe oesophageal side effects is thought to be greater in patients who do not take alendronate correctly and/or continue to take alendronate after developing symptoms indicative of oesophageal irritation. It is very important that complete administration instructions are given to, and understood, by the patient (see section 4.2). Patients should be informed that the risk of oesophageal problems may increase if they do not follow these instructions.


While no increased risk was observed in extensive clinical trials, there have been rare (post-marketing) reports of gastric and duodenal ulcers, some of them severe and with complications.


Renal impairment

Alendronate is not recommended for patients with impaired renal function if the GFR is less than 35 ml/min (see section 4.2).


Bone and mineral metabolism

Causes of osteoporosis other than oestrogen deficiency, ageing and glucocorticoid use should be considered.

Hypocalcaemia must be corrected before treatment with alendronate is initiated (see section 4.3). Other disorders affecting mineral metabolism (such as vitamin D deficiency and hypoparathyroidism) should also be effectively treated before starting alendronate. In patients with these conditions, serum calcium and symptoms of hypocalcaemia should be monitored during treatment with alendronate.


Due to the positive effects of alendronate in increasing bone mineral, decreases in serum calcium and phosphate may occur especially in patients taking glucocorticoids in whom calcium absorption may be decreased. These are usually small and asymptomatic. However, there have been rare reports of symptomatic hypocalcemia, which have occasionally been severe and often occurred in patients with predisposing conditions (e.g. hypoparathyroidism, vitamin D deficiency and in cases of calcium malabsorption).


It is particularly important to ensure that patients taking glucocorticoids have an adequate calcium and vitamin D intake.


Atypical fractures of the femur

Atypical subtrochanteric and diaphyseal femoral fractures have been reported with bisphosphonate therapy, primarily in patients receiving long-term treatment for osteoporosis. These transverse or short oblique, fractures can occur anywhere along the femur from just below the lesser trochanter to just above the supracondylar flare. These fractures occur after minimal or no trauma and some patients experience thigh or groin pain, often associated with imaging features of stress fractures, weeks to months before presenting with a completed femoral fracture. Fractures are often bilateral; therefore the contralateral femur should be examined in bisphosphonate-treated patients who have sustained a femoral shaft fracture. Poor healing of these fractures has also been reported. Discontinuation of bisphosphonate therapy in patients suspected to have an atypical femur fracture should be considered pending evaluation of the patient, based on an individual benefit risk assessment.

During bisphosphonate treatment patients should be advised to report any thigh, hip or groin pain and any patient presenting with such symptoms should be evaluated for an incomplete femur fracture.


Osteonecrosis of the jaw

Osteonecrosis of the jaw, generally associated with tooth extraction and/or local infection (including osteomyelitis) has been reported in patients with cancer receiving treatment regimens including primarily intravenously administered bisphosphonates. Many of these patients were also receiving chemotherapy and corticosteroids. Osteonecrosis of the jaw has also been reported in patients with osteoporosis receiving oral bisphosphonates.


The following risk factors should be considered when evaluating an individual’s risk of developing osteonecrosis of the jaw:

• potency of the bisphosphonate (highest for zoledronic acid), route of administration (see above) and cumulative dose

• cancer, chemotherapy, radiotherapy, corticosteroids, angiogenesis inhibitors, smoking

• a history of dental disease, poor oral hygiene, periodontal disease, invasive dental procedures and poorly fitting dentures.


A dental examination with appropriate preventive dentistry should be considered prior to treatment

with oral bisphosphonates in patients with poor dental status.


While on treatment, these patients should avoid invasive dental procedures if possible. For patients who develop osteonecrosis of the jaw while on bisphosphonate therapy, dental surgery may exacerbate the condition. For patients requiring dental procedures, there are no data available to suggest whether discontinuation of bisphosphonate treatment reduces the risk of osteonecrosis of the jaw.


Clinical judgement of the treating physician should guide the management plan of each patient based on individual benefit/risk assessment.


During bisphosphonate treatment, all patients should be encouraged to maintain good oral hygiene,

receive routine dental check-ups, and report any oral symptoms such as dental mobility, pain, or

swelling.


Osteonecrosis of the external auditory canal

Osteonecrosis of the external auditory canal has been reported with bisphosphonates, mainly in association with long-term therapy. Possible risk factors for osteonecrosis of the external auditory canal include steroid use and chemotherapy and/or local risk factors such as infection or trauma. The possibility of osteonecrosis of the external auditory canal should be considered in patients receiving bisphosphonates who present with ear symptoms including chronic ear infections.


Musculoskeletal pain

Bone, joint, and/or muscle pain has been reported in patients taking bisphosphonates. In post-marketing experience, these symptoms have rarely been seen and/or incapacitating (see section 4.8). The time to onset of symptoms varied from one day to several months after starting treatment. Most patients had relief of symptoms after stopping treatment. A subset had recurrence of symptoms when rechallenged with the same medicinal product or another bisphosphonate.


Skin reactions

In post-marketing experience, there have been rare reports of severe skin reactions including

Stevens Johnson syndrome and toxic epidermal necrolysis.


Excipients

Alendronat Hexal tablets contain lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.


4.5 Interaction with other medicinal products and other forms of interaction


If taken at the same time, it is likely that foods and drinks (including mineral water), calcium supplements, antacids and some oral medicines will affect the absorption of alendronate. Patients must therefore wait for at least 30 minutes after taking alendronate before taking any other oral medicine (see sections 4.2 and 5.2).


No other clinically significant active substance interactions are expected. A number of patients in the clinical trials received oestrogen (intravaginally, transdermally or orally) concomitantly with alendronate. No undesirable effects could be related to the combination treatment.


Since NSAID use is associated with gastrointestinal irritation, caution should be used during concomitant use with alendronate.


No specific interaction studies have been carried out, but alendronate was used in clinical trials concomitantly with a number of other commonly prescribed medicines without any evidence of clinically unfavourable interactions.


4.6 Fertility, pregnancy and lactation


Pregnancy

There are no or limited amount of data from the use of alendronate in pregnant women. Studies in animals have shown reproductive toxicity.

Alendronate should not be used in pregnancy. Alendronate given to pregnant rats caused hypocalcaemia-related dystocia (see section 5.3).


Breast-feeding

It is not known whether alendronate/metabolites are excreted into breast milk in humans. A risk to the newborns/infants cannot be excluded. Alendronate should not be used by breast-feeding women.


Fertility

Bisphosphonates are incorporated into the bone matrix, from which they are gradually released over a period of years. The amount of bisphosphonate incorporated into adult bone, and hence, the amount available for release back into the systemic circulation, is directly related to the dose and duration of bisphosphonate use (see section 5.2). There are no data on foetal risk in humans. However, there is a theoretical risk of foetal harm, predominantly skeletal, if a woman becomes pregnant after completing a course of bisphosphonate therapy. The impact of variables such as time between cessation of bisphosphonate therapy to conception, the particular bisphosphonate used, and the route of administration (intravenous versus oral) on the risk has not been studied.


4.7 Effects on ability to drive and use machines


Alendronate has no or negligible direct influence on the ability to drive and use machines.

Certain side effects have been reported during treatment with alendronate which may, in some patients, impair the ability to drive or use machines. The reaction to alendronate may differ from individual to individual (see section 4.8).


4.8 Undesirable effects


Summary of the safety profile

In a one-year study in post-menopausal women with osteoporosis the overall safety profiles for alendronate once-weekly 70 mg tablets (n=519) and alendronate 10 mg daily (n=370) were similar.


In two three-year studies of almost identical design, with post-menopausal women (alendronate 10 mg: n=196; placebo: n=397) the overall safety profiles for alendronate 10 mg daily and placebo were similar.


Adverse experiences reported by the investigators as possibly, probably or definitely drug-related

are presented below if they occurred in ≥1% in either treatment group in the one-year study, or in

≥1% of patients treated with alendronate 10 mg/day and at a greater incidence than in patients given

placebo in the three-year studies:

The one-year study

Three-year studies

Alendronate once-weekly 70 mg (n=519) %

Alendronate

10 mg daily

(n=370) %

Alendronate

10 mg daily

(n=196) %

Placebo

(n=397) %

Gastrointestinal

Abdominal pain

3.7

3.0

6.6

4.8

Dyspepsia

2.7

2.2

3.6

3.5

Acid regurgitation

1.9

2.4

2.0

4.3

Nausea

1.9

2.4

3.6

4.0

Abdominal distension

1.0

1.4

1.0

0.8

Constipation

0.8

1.6

3.1

1.8

Diarrhoea

0.6

0.5

3.1

1.8

Dysphagia

0.4

0.5

1.0

0.0

Flatulence

0.4

1.6

2.6

0.5

Gastritis

0.2

1.1

0.5

1.3

Gastric ulcer

0.0

1.1

0.0

0.0

Oesophageal ulcer

0.0

0.0

1.5

0.0

Musculoskeletal



Musculoskeletal pain

(bone, muscle or joints)

2.9

3.2

4.1

2.5

Muscle cramps

0.2

1.1

0.0

1.0

Neurological



Headache

0.4

0.3

2.6

1.5

The following undesirable effects have also been reported during clinical studies and/or post marketing:

Frequencies are defined as:

Very common: ( 1/10)

Common: ( 1/100 to < 1/10)

Uncommon: ( 1/1,000 to < 1/100)

Rare: ( 1/10,000 to < 1/1,000)

Very rare: (< 1/10,000)


Immune system disorders:

Rare: hypersensitivity reactions including urticaria and angioedema


Metabolism and nutrition disorders:

Rare: symptomatic hypocalcaemia, often in association with predisposing conditions.§


Nervous system disorders:

Common: headache, dizziness†

Uncommon: dysgeusia†


Eye disorders:

Uncommon: eye inflammation (uveitis, scleritis, episcleritis)


Ear and labyrinth disorders:

Common: vertigo†

Very rare:Osteonecrosis of the external auditory canal (bisphosphonate class adverse reaction)


Gastrointestinal disorders

Common: abdominal pain, dyspepsia, constipation, diarrhoea, flatulence, oesophageal ulcer*, dysphagia*, abdominal distension, acid regurgitation

Uncommon: nausea, vomiting, gastritis, oesophagitis*, oesophageal erosions*, melena†

Rare: oesophageal stricture*, oropharyngeal ulceration*, upper gastrointestinal PUBs (perforation, ulcers, bleeding) §


Skin and subcutaneous tissue disorders:

Common: alopecia†, pruritus†

Uncommon: rash, erythema

Rare: rash with photosensitivity, severe skin reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis‡


Musculoskeletal and connective tissue disorders:

Very common: musculoskeletal (bone, muscle or joint) pain which is sometimes severe†§

Common: joint swelling†

Rare: Osteonecrosis of the jaw‡§,atypical subtrochanteric and diaphyseal femoral fractures (bisphosphonate class adverse reaction)


General disorders and administration site conditions:

Common: asthenia†, peripheral oedema†

Uncommon: transient symptoms as in an acute-phase response (myalgia, malaise and rarely, fever), typically in association with initiation of treatment†.

§See section 4.4

†Frequency in Clinical Trials was similar in the drug and placebo group.

*See sections 4.2 and 4.4

‡This adverse reaction was identified through post-marketing surveillance. The frequency of rare was estimated based on relevant clinical trials

Identified in postmarketing experience.


Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.


4.9 Overdose


Symptoms

Hypocalcaemia, hypophosphataemia and upper gastrointestinal side effects such as upset stomach, heartburn, oesophagitis, gastritis or ulcer can occur on oral overdosage.


Management

There is no specific information available with regard to overdosage with alendronate. Milk or antacids should be given in order to bind alendronate. On account of the risk of oesophageal irritation, vomiting should not be induced and the patient should be kept in an upright position.


5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Drugs for treatment of bone diseases, bisphosphonates.

ATC code: M05BA04


The active substance in Alendronat Hexaltablets, sodium alendronate trihydrate, is a bisphosphonate that inhibits osteoclastic bone resorption without any direct effect on bone formation. Preclinical studies have demonstrated a preference for localisation of alendronate to sites where active resorption takes place. Osteoclastic activity is inhibited, but formation and binding of the osteoclasts is not affected. Bone formed during treatment with alendronate is of normal quality.


Treatment of post-menopausal osteoporosis

Osteoporosis is defined as bone mineral density (BMD) of the spine or hip 2.5 standard deviations below the mean value of a normal young population or as a previous fragility fracture, irrespective of bone mineral density.


The therapeutic equivalence of alendronate once-weekly tablets (n=519) and alendronate 10 mg daily (n=370) was demonstrated in a one-year multicentre study in post-menopausal women with osteoporosis. The mean increase from baseline of BMD in the lumbar spine after one year was 5.1 % (95 % confidence interval: 4.8, 5.4 %) in the group receiving 70 mg once per week and 5.4 % (95 % confidence interval: 5.0, 5.8 %) in the group receiving 10 mg daily. The average increases in BMD in the group receiving 70 mg once per week and in the group receiving 10 mg daily were 2.3 % and 2.9 % in the femoral neck and 2.9 % and 3.1 % over the total hip. The two treatment groups were also similar with regard to increased bone density in other parts of the skeleton.


The effects of alendronate on BMD and fracture incidence in post-menopausal women were studied in two initial efficacy studies of identical design (n=994), and in the Fracture Intervention Trial (FIT: n=6459).


In the initial efficacy studies, the increases in BMD with alendronate 10 mg daily relative to placebo after three years were 8.8 %, 5.9 % and 7.8 % at the spine, femoral neck and trochanter respectively. Total BMD also increased significantly. In the patients treated with alendronate, the proportion of patients who suffered one or more vertebral fractures was reduced by 48 % (alendronate 3.2 % versus placebo 6.2 %). In the two-year extensions of these studies the BMD in the spine and trochanter continued to increase. In addition, BMD at the femoral neck and total body was maintained.


The FIT study included two placebo-controlled trials in which alendronate was given daily (5 mg daily for two years and 10 mg daily for a further one or two years).


Osteoporosis in men with increased risk of fracture

The efficacy of alendronate 10 mg once daily in men (31-87 years, mean age 63 years, n=241) with osteoporosis was evaluated in a two-year study. After two years of treatment with alendronate 10 mg/day, BMD increased on average by 5.3 % in the spine, by 2.6 % in the femoral neck, by 3.1 % in the trochanter, and by 1.6 % for the skeleton as a whole, relative to placebo (p<0.001 for all measurement points). The effect of alendronate on BMD was independent of age, race, gonadal function, baseline BMD or baseline bone turnover. The incidence of new vertebral fractures was evaluated as a safety variable. In a retrospective analysis (assessed by quantitative radiography) one new fracture (0.8 %) was documented among patients treated with alendronate, compared with 6 new fractures (7.1 %) for placebo (p=0.017). The reduction in height was less after treatment with alendronate, relative to placebo (-0.6 mm and ‑2.4 mm respectively, p=0.02). No effect on non-vertebral fractures was seen.


Glucocorticoid-induced osteoporosis

Long-term use of steroids is often associated with the development of osteoporosis accompanied by fractures. This occurs in both men and women of all ages. The efficacy of alendronate 10 mg and alendronate 5 mg once daily in men and women treated with steroids (at least 7.5 mg/day of prednisone or equivalent, median dose 10 mg/day) was demonstrated in two one-year studies of practically identical design. These studies involved a total of 560 patients aged 17-83 years. The patients received calcium and vitamin D supplements. Relative to placebo, BMD increased significantly in the spine (2.41 %), femoral neck (2.19 %) and trochanter (1.65 %) in patients who were treated with alendronate 5 mg once daily. The increases in BMD with alendronate 10 mg once daily were the same as for alendronate 5 mg once daily in all patients, with the exception of post-menopausal women who were not being treated with oestrogen. In these women the increases (relative to placebo) with alendronate 10 mg once daily were greater than for alendronate 5 mg once daily in the spine (4.11 % versus 1.56 %) and trochanter (2.84 % versus 1.67 %). The fracture-preventing effect of increasing bone density with alendronate 10 mg or alendronate 5 mg in corticosteroid-induced osteoporosis has not been established.


Alendronate 10 mg and 5 mg were effective irrespective of the dose or duration of steroid use. In addition, alendronate 10 mg and alendronate 5 mg were effective irrespective of age (<65 years as against 65 years), gender, baseline BMD, baseline bone turnover and concomitant use of a number of common medicines. In the patients who received alendronate in doses up to 10 mg daily and in whom biopsy was performed after one year no signs of a disturbance of the bone mineralisation process were seen.


Laboratory test findings

In clinical studies, asymptomatic, mild and transient decreases in serum calcium and phosphate were observed in approximately 18 and 10%, respectively, of patients taking alendronate 10 mg/day versus approximately 12 and 3% of those taking placebo. However, the incidences of decreases in serum calcium to <8.0 mg/dl (2.0 mmol/l) and serum phosphate to ≤2.0 mg/dl (0.65 mmol/l) were similar in both treatment groups.


Paediatric patients

Alendronate sodium has been studied in a small number of patients with osteogenesis imperfecta under the age of 18 years. Results are insufficient to support the use of alendronate sodium in paediatric patients with osteogenesis imperfecta.


5.2 Pharmacokinetic properties


Absorption

Compared with an intravenous reference dose, the mean oral bioavailability of alendronate in women was 0.64 % for doses ranging from 5 to 70 mg given after an overnight fast and two hours before a standardised breakfast. Bioavailability decreased to an estimated 0.46 % and 0.39 % when alendronate was given an hour or half an hour before a standardised breakfast.

In osteoporosis studies alendronate was effective when it was given at least 30 minutes before the first meal or drink of the day. Bioavailability was negligible irrespective of whether alendronate was given together with or up to two hours after a standardised breakfast. Concomitant administration of alendronate with coffee or orange juice reduced bioavailability by approx. 60 %. In healthy persons, oral prednisolone (20 mg three times daily for five days) did not result in any clinically meaningful change in the oral bioavailability of alendronate (a mean increase ranging from 20 % to 44 %).


Distribution

Studies in rats show that alendronate is initially distributed to soft tissues after intravenous administration of 1 mg/kg, but is then rapidly redistributed to the skeleton or excreted in the urine. The mean steady-state volume of distribution, exclusive of bone, is at least 28 litres in humans. Concentrations of active substance in plasma following therapeutic oral doses are too low for analytical detection (<5 ng/ml). Protein binding in human plasma is approximately 78%.


Biotransformation

There is no evidence that alendronate is metabolised in animals or humans.


Elimination

Following a single intravenous dose of (14C) alendronate, approximately 50% of the radioactivity was excreted in the urine within 72 hours and little or no radioactivity was recovered in the faeces. Following a single intravenous dose of 10 mg, the renal clearance of alendronate was 71 ml/min, and systemic clearance did not exceed 200 ml/min. Plasma concentrations fell by more than 95% within 6 hours following intravenous administration. The terminal half-life in humans is estimated to exceed ten years, reflecting release of alendronate from the skeleton. Alendronate is not excreted through the acidic or basic transport systems of the kidney in rats, and thus it is not thought to interfere with the excretion of other active substances by those systems in humans.


Renal impairment

Preclinical studies show that the active substance that is not deposited in bone is rapidly excreted in the urine. No evidence of saturation of bone uptake was found after chron

ic dosing with cumulative intravenous doses up to 35 mg/kg in animals. Although no clinical information is available, it is likely that, as in animals, elimination of alendronate via the kidney will be reduced in patients with impaired renal function. Therefore, somewhat greater accumulation of alendronate in bone might be expected in patients with impaired renal function (see section 4.2).


5.3 Preclinical safety data

Non-clinical data of general toxicity, genotoxicity and carcinogenicity did not reveal any special risks for humans. Studies in female rats showed that treatment with alendronate during pregnancy was associated with dystocia during parturition, which was related to hypocalcaemia. Studies in which rats were given high doses showed an increased incidence of incomplete foetal bone formation. The relevance for humans is unknown.


6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Microcrystalline cellulose

Lactose monohydrate

Croscarmellose sodium

Magnesium stearate


6.2 Incompatibilities

Not applicable.


6.3 Shelf life

3 years


6.4 Special precautions for storage

Do not store above 25 °C. Store in the original package in order to protect from moisture.


6.5 Nature and contents of container

Triplex blister: PVC/PE/PVDC/ALU

14, 28, 56, 98, 112 and 50 x 1 (unit dose) tablets.

Not all pack sizes may be marketed.


6.6 Special precautions for disposal


No special requirements.


7. MARKETING AUTHORISATION HOLDER


[To be completed nationally]


8. MARKETING AUTHORISATION NUMBER(S)


[To be completed nationally]


9. DATE OF FIRST AUTHORISATION/ RENEWAL OF THE AUTHORISATION


Date of first authoristaion: {DD month YYYY}

Date of latest renewal: {DD month YYYY}

[To be completed nationally]


10. DATE OF REVISION OF THE TEXT


2016-08-19

{DD month YYYY}

[To be completed nationally]